Gamida Cell - Cord Blood Transplant

Press Releases

Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016
Dec. 6, 2016
SCD patients treated with NiCord showed rapid engraftment and were cured of disease symptoms

Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board
Nov. 21, 2016

Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord®
Oct. 11, 2016
NiCord is a novel graft modality for bone marrow transplantation in patients with hematological malignancies including leukemia and lymphoma

Gamida Cell Announces Appointment of Julian Adams, Ph.D.and Kenneth I. Moch to its Board of Directors
Sep. 15, 2016
New directors bring extensive experience in building and overseeing corporate strategy of growing life sciences companies to Board

Gamida Cell Announces First Patient with Sickle Cell Disease Transplanted in Phase 1/2 Study of CordIn™ as the Sole Graft Source
Jul. 27, 2016
CordIn has the potential to be a sole graft source for rare genetic diseases where transplantation is the only clinically established cure

Gamida Cell Presents Data From Phase 1/2 Study of NiCord® for High Risk Hematological Malignancies at ASCO 2016
Jun. 6, 2016
Patients treated with NiCord showed improved engraftment, reduced morbidity and less transplant related mortality compared to controls

Gamida Cell Announces $4.4 Million Grant from the Israeli Government
May. 23, 2016
Non-dilutive funding will support further development of NiCord® for blood cancers, CordIn® for rare genetic diseases and NK cells for immune therapy of cancer

Gamida Cell Presents Additional Positive Data of NiCord® in Blood Cancer Patients at EBMT 2016
Apr. 5, 2016
Data demonstrate rapid engraftment, reduced bacteria infections and shortened hospitalization

Gamida Cell Reports Positive Top Line Results of International, Multi-Center, Phase I/II Study of NiCord® for Blood Cancers, Demonstrating Rapid and Durable Hematopoietic Recovery
Dec. 7, 2015

Gamida Cell Announces Strategic Equity Investment by Major Pharmaceutical Company
Oct. 12, 2015

Gamida Cell Achieves Major Regulatory Milestone: FDA and EMA Respond Positively to NiCord® Phase III Study Design Outline
Aug. 10, 2015

First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell’s Ongoing Phase I/II Clinical Trial for Blood Cancers
Jan. 8, 2015

Gamida Cell’s NiCord® Receives FDA and EMA Orphan Drug Designation
Jan. 6, 2015

Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Aug. 19, 2014

Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration
Sep. 9, 2013

Press Releases Archive


To learn more about our products and clinical trials, please fill in:
* Message: